Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers

S. Park, JaSeung Koo, M. S. Kim, H. S. Park, J. S. Lee, J. S. Lee, S. I. Kim, Byeongwoo Park, K. S. Lee

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR. Results: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.

Original languageEnglish
Pages (from-to)1755-1762
Number of pages8
JournalAnnals of Oncology
Volume22
Issue number8
DOIs
Publication statusPublished - 2011 Aug 5

Fingerprint

Androgen Receptors
Estrogen Receptors
Breast Neoplasms
Neoplasms
Survival
Proportional Hazards Models
Disease-Free Survival
Multivariate Analysis
Demography
Hormones

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Park, S. ; Koo, JaSeung ; Kim, M. S. ; Park, H. S. ; Lee, J. S. ; Lee, J. S. ; Kim, S. I. ; Park, Byeongwoo ; Lee, K. S. / Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. In: Annals of Oncology. 2011 ; Vol. 22, No. 8. pp. 1755-1762.
@article{618c705e500b4f53aff3a25a5845220a,
title = "Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers",
abstract = "Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10{\%} nuclear-stained cells were considered positive for AR. Results: AR was expressed in 58.1{\%} of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.",
author = "S. Park and JaSeung Koo and Kim, {M. S.} and Park, {H. S.} and Lee, {J. S.} and Lee, {J. S.} and Kim, {S. I.} and Byeongwoo Park and Lee, {K. S.}",
year = "2011",
month = "8",
day = "5",
doi = "10.1093/annonc/mdq678",
language = "English",
volume = "22",
pages = "1755--1762",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. / Park, S.; Koo, JaSeung; Kim, M. S.; Park, H. S.; Lee, J. S.; Lee, J. S.; Kim, S. I.; Park, Byeongwoo; Lee, K. S.

In: Annals of Oncology, Vol. 22, No. 8, 05.08.2011, p. 1755-1762.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers

AU - Park, S.

AU - Koo, JaSeung

AU - Kim, M. S.

AU - Park, H. S.

AU - Lee, J. S.

AU - Lee, J. S.

AU - Kim, S. I.

AU - Park, Byeongwoo

AU - Lee, K. S.

PY - 2011/8/5

Y1 - 2011/8/5

N2 - Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR. Results: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.

AB - Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR. Results: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.

UR - http://www.scopus.com/inward/record.url?scp=79960989401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960989401&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq678

DO - 10.1093/annonc/mdq678

M3 - Article

C2 - 21310761

AN - SCOPUS:79960989401

VL - 22

SP - 1755

EP - 1762

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -